The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...
The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery ...
The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback